Companies · Biotechnology

Novuson Surgical, Inc.

BOTHELL · Biotechnology

Diligence memoA one-page analyst read on Novuson Surgical, Inc. — recommendation, valuation, rhythm, risks.
$2.9M
Total raised · real
2
Rounds
4.8×
Latest step-up
Top 68%
Sector rank · raised
Seed
Latest stage · inferred · Fri Sep 01 2017 00:00:00 GMT+0000 (Coordinated Universal Time)

Novuson Surgical, Inc. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.49× the median modeled value of Seed Biotechnology companies in 2016–2018 (175 peers) — value vs value, same stage and era.
  • Within the normal band (149% of peer median) for its niche.
Dormant
  • Last raise 8.8 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Novuson Surgical, Inc. is one of 4293 Biotechnology companies tracked from BOTHELL. By capital raised it ranks in the long tail (ahead of 33% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

medical-devices

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
29
Investors (latest)
2017-09-01
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MPre-Seed · 2015-10-06 Raised $500K (real) Modeled valuation $28M (est)$500K$28MPre-Seed2015Seed · 2017-09-01 Raised $2.4M (real) Modeled valuation $106M (est)$2.4M$106MSeed2017+$2.4MCumulative $2.9M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$500K · 2015
Seed$2.4M · 2017

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$105.8M
Base estimate est.
$1.7M
Conservative case
$830.0M
Upside case
$11.9M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $27.6M · 2015-10-062015Seed · modeled $105.8M · 2017-09-012017
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
32%
Survival probability
14% low · 50% high
1.74×/yr
Annual markup
2.28×/yr upside case
6.0 yr
Elapsed time used
8.8 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
23 mo
Avg between rounds
$1.5M/yr
Capital velocity
10.7 yr
On record since
2015
First round
2
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.4× of median
This company$2.9M
Sector median$7.2M
Latest round — vs other Seed rounds in sector (real $, this stage) 1.4× above median
This company$2.4M
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 1.6× above median
This company$105.8M
Sector median$64.2M

Raised more than 33% of sector peers (real $). Modeled value above 59% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #45 of 175.

This companyCohort peer
$100.0M$1.0B$1.0M$10.0MCapital raised (log)Mimedx Group, Inc. · Seed Raised $8.2M · modeled $177.6M (est)Kenjockety Biotechnology, LLC · Seed Raised $4.0M · modeled $177.6M (est)Helocyte, Inc. · Seed Raised $4.0M · modeled $177.5M (est)CytoDel, INC. · Seed Raised $4.1M · modeled $173.4M (est)Finch Therapeutics, Inc. · Seed Raised $4.5M · modeled $165.8M (est)Cordex Systems, Inc · Seed Raised $6.4M · modeled $164.2M (est)Viking Therapeutics, Inc. · Seed Raised $3.7M · modeled $162.3M (est)Escalier Biosciences B.V. · Seed Raised $3.5M · modeled $155.4M (est)Corino Therapeutics, Inc. · Seed Raised $3.5M · modeled $154.3M (est)Captozyme Inc. · Seed Raised $3.4M · modeled $151.0M (est)BluDiagnostics, Inc. · Seed Raised $4.5M · modeled $151.0M (est)FORGE Life Science, LLC · Seed Raised $3.6M · modeled $149.5M (est)Novuson Surgical, Inc. (this company) Raised $2.9M · modeled $105.8M (est)Novuson Surgical, Inc.
CompanyStageRaised · realValue · estvs peer med.
Mimedx Group, Inc.Seed$8.2M$177.6M2.50×
Kenjockety Biotechnology, LLCSeed$4.0M$177.6M2.50×
Helocyte, Inc.Seed$4.0M$177.5M2.50×
CytoDel, INC.Seed$4.1M$173.4M2.44×
Finch Therapeutics, Inc.Seed$4.5M$165.8M2.33×
Cordex Systems, IncSeed$6.4M$164.2M2.31×
Viking Therapeutics, Inc.Seed$3.7M$162.3M2.28×
Escalier Biosciences B.V.Seed$3.5M$155.4M2.19×
Corino Therapeutics, Inc.Seed$3.5M$154.3M2.17×
Captozyme Inc.Seed$3.4M$151.0M2.12×
BluDiagnostics, Inc.Seed$4.5M$151.0M2.12×
FORGE Life Science, LLCSeed$3.6M$149.5M2.10×
Novuson Surgical, Inc. this companySeed$2.9M$105.8M1.49×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$500K2015-10-06$2.8M$27.6M85%
Seed$2.4M2017-09-01$11.9M$105.8M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$500K2015-10-06
    • First recorded raise — entered as Pre-Seed.
    • 1 investor on this round.
  2. Seed$2.4M2017-09-01
    • Raised again after 23 mo — slower than the ~14 mo sector norm.
    • Round 4.8× larger than the prior — scaling up.
    • 29 investors on this round.
Intelligence
2019 ~Q3
Modeled next raise · ~23mo cadence
$7.1M
Modeled next size est.range $4.6M$11.4M
4.8×
Last step-up
$1.5M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Christoph E Mack1 other2015-10
Francesco P Curra2015-10
Stuart B Mitchell2015-10
Registry & provenance

Novuson Surgical, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1655934
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Kineta Two, LLCBiotechnologySeed$2.9M$121.5Msame sector · same stage
Inspired Life Medical, Inc.BiotechnologySeed$2.9M$127.4Msame sector · same stage
Capio Biosciences, Inc.BiotechnologySeed$2.9M$128.8Msame sector · same stage
Cancer Targeting Systems, Inc.BiotechnologySeed$2.9M$128.8Msame sector · same stage
Inhalon Biopharma, Inc.BiotechnologySeed$2.9M$120.0Msame sector · same stage
Mithridion IncBiotechnologySeed$2.9M$129.1Msame sector · same stage
IntelliStay CY Tulsa Equity LLCBiotechnologySeed$2.9M$126.8Msame sector · same stage
Lantern Pharma Inc.BiotechnologySeed$2.9M$105.9Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Assurtek Surgical, Inc.BiotechnologyPre-Seed$1.4M84%
Virtuoso Surgical, Inc.BiotechnologySeries A$49.7M84%
Petal Surgical, Inc.BiotechnologySeries B$78.0M84%
AMB Surgical II, LLCBiotechnologyPre-Seed$23.1M84%
Ventaris Surgical, Inc.BiotechnologySeries B$114.2M84%
Surgical Training Simulators, Inc.BiotechnologyPre-Seed$657K82%
Amend Surgical, Inc.BiotechnologySeed$5.2M81%
Maximum Fidelity Surgical Simulations, Inc.BiotechnologySeed$11.1M81%
Frequently asked
How much funding has Novuson Surgical, Inc. raised?
Novuson Surgical, Inc. has raised approximately $2.9M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Novuson Surgical, Inc.'s estimated valuation?
Provath's modeled valuation for Novuson Surgical, Inc. is approximately $105.8M (modeled range $1.7M–$830.0M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Novuson Surgical, Inc. at?
Novuson Surgical, Inc.'s latest modeled financing stage is Seed. Its most recent recorded round closed around Fri Sep 01.
What does Novuson Surgical, Inc. do and where is it based?
Novuson Surgical, Inc. operates in the Biotechnology sector, based in BOTHELL.
Explore related

See where Novuson Surgical, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Novuson Surgical, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.